Article
Anecortave acetate administration shows promise for subfoveal, exudative AMD
San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
